Edgewise Therapeutics, Inc. EWTX
39.34
(1.82)
(4.42%)
as of 25 Sep
- Market cap
- $4.4B
- P/E
- 0.0×
Follow EWTX
Insider Buys
alert about insiders buying in the last 12 month
| Dec '17 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Current Ratio |
— | 29.86 | 26.97 | 21.53 | 19.50 | 19.93 | 19.85 |
Net Debt/EBITDA |
— | 7.59 | 6.54 | 4.91 | 2.61 | 2.78 | 2.69 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
— | 0.85 | 0.78 | 0.78 | 0.92 | 0.81 | 0.86 |
Capex/Depreciation |
— | (1.10) | (2.46) | 1,109.20 | 0.74 | 0.13 | 0.05 |
Interest Coverage |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | (14.21%) | (35.53%) | (21.78%) | (30.10%) | (34.40%) | (34.19%) | |
| — | (26.11%) | (20.56%) | (20.74%) | (28.33%) | (32.37%) | (32.29%) | |
ROIC |
— | 0.00% | 0.00% | 0.00% | (16,355.41%) | 0.00% | 0.00% |
Return on Tangible Assets |
— | (13.61%) | (15.62%) | (19.38%) | (31.24%) | (29.02%) | (32.03%) |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
— | (20.08) | (0.91) | (1.09) | (1.53) | (1.19) | (1.40) |
Cash per Share |
— | 174.69 | 7.48 | 6.57 | 5.00 | 5.09 | 5.15 |
Shareholders Equity per Share |
— | 171.58 | 7.31 | 6.47 | 5.00 | 4.97 | 5.07 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | 171.58 | 7.31 | 6.47 | 5.00 | 4.97 | 5.07 |
Free Cash Flow |
— | (14.84) | (34.17) | (58.18) | (97.69) | (110.34) | (144.07) |
Working Capital |
— | 125.30 | 273.25 | 340.41 | 310.23 | 451.62 | 516.02 |
Capital Expenditures |
— | (0.20) | (0.67) | (5.55) | (5.74) | (1.31) | (0.26) |
Net Current Asset Value |
— | 125.30 | 272.92 | 336.61 | 305.79 | 447.88 | 513.04 |
| Other line items | |||||||
Quick Ratio |
— | 29.73 | 26.69 | 21.22 | 18.98 | 19.71 | 19.37 |
Depreciation/Fixed assets |
— | 0.36 | 0.30 | 0.00 | (0.75) | (1.08) | (0.69) |
Cash ROIC |
— | (5.92%) | (6.20%) | (8.76%) | (16.07%) | (12.75%) | (14.41%) |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
— | (19.80) | (0.89) | (0.98) | (1.44) | (1.18) | (1.40) |
Capex per Share |
— | (0.27) | (0.02) | (0.10) | (0.09) | (0.01) | 0.00 |
Average Payables |
— | 2.71 | 2.71 | 4.97 | 5.07 | 4.80 | 5.79 |
Average Assets |
— | 65.57 | 208.18 | 326.17 | 353.57 | 413.43 | 519.71 |
Average Common Equity |
— | 120.48 | 120.48 | 310.55 | 332.77 | 389.02 | 490.74 |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Profit Margin |
— | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates